Barclays
BDTX icon

Barclays’s Black Diamond Therapeutics BDTX Stock Holding History

Barclays’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.1K Sell
40,057
-27,222
-40% -$66.6K ﹤0.01% 4178
2026
Q1 		$143K Sell
67,279
-7,531
-10% -$17.9K ﹤0.01% 3871
2025
Q4 		$182K Buy
74,810
+51,942
+227% +$184K ﹤0.01% 4370
2025
Q3 		$86.7K Sell
22,868
-7,002
-23% -$20.5K ﹤0.01% 4651
2025
Q2 		$74.1K Sell
29,870
-36,774
-55% -$70.9K ﹤0.01% 4642
2025
Q1 		$103K Sell
66,644
-19,901
-23% -$41.7K ﹤0.01% 4394
2024
Q4 		$185K Buy
86,545
+8,394
+11% +$24.1K ﹤0.01% 4349
2024
Q3 		$340K Buy
78,151
+52,265
+202% +$284K ﹤0.01% 4008
2024
Q2 		$121K Sell
25,886
-141,360
-85% -$759K ﹤0.01% 3819
2024
Q1 		$848K Hold
167,246
– – ﹤0.01% 3245
2023
Q4 		$470K Sell
167,246
-155,000
-48% -$364K ﹤0.01% 3914
2023
Q3 		$925K Buy
322,246
+197,895
+159% +$729K ﹤0.01% 2384
2023
Q2 		$628K Buy
124,351
+105,000
+543% +$214K ﹤0.01% 2608
2023
Q1 		$36.6K Hold
19,351
– – ﹤0.01% 4516
2022
Q4 		$34.8K Sell
19,351
-1,584
-8% -$2.85K ﹤0.01% 4669
2022
Q3 		$35K Sell
20,935
-1,057
-5% -$3.26K ﹤0.01% 3878
2022
Q2 		$54K Sell
21,992
-4,388
-17% -$10.2K ﹤0.01% 4006
2022
Q1 		$73K Buy
+26,380
New +$96.3K ﹤0.01% 3930

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Barclays's BDTX Position: Q2 2026 in Review

Barclays reduced its Black Diamond Therapeutics (BDTX) stake by 40% in Q2 2026, selling an estimated $66.6K and leaving 40,057 shares worth $74.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4178.

Barclays first reported a position in BDTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $925K in Q3 2023. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Barclays held 40,057 shares of Black Diamond Therapeutics worth $74.1K as of Q2 2026.
  • Barclays sold 27,222 Black Diamond Therapeutics shares in Q2 2026, an estimated $66.6K.
  • Black Diamond Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4178 holding.
  • Barclays first reported a position in Black Diamond Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Black Diamond Therapeutics position peaked at $925K in Q3 2023.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.